Gilead Sciences reported strong third-quarter results, with revenue reaching $7.55 billion, surpassing analyst expectations of $7.00 billion by $545 million. The company's earnings per share (EPS) were $2.02, exceeding the anticipated $1.55, although this figure represents a decline of 11.79% year-over-year. In response to the robust performance, Gilead raised its full-year product sales guidance by $150 million, bringing the new midpoint estimate to $26 billion, excluding Veklury. The results reflect a 7% year-over-year increase in sales, prompting the company to enhance its outlook for full-year earnings.